Literature DB >> 20587910

Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population.

Z Sabahi1, R Salek, R E Heravi, F Mosaffa, Z J Avanaki, J Behravan.   

Abstract

BACKGROUND: The allele frequency of the multidrug resistance 1 (MDR1) gene C3435T polymorphism differs with different ethnic populations, such as Asian, African, and Caucasian. This polymorphism has been reported to be associated with the increase of gastric cancer.
OBJECTIVES: The objective of this study was to find out the association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population.
MATERIALS AND METHODS: In this study, 48 gastric cancer patients were diagnosed. Genomic DNA was extracted by a salting-out method. The MDR1 polymorphism was studied by a polymerase chain reaction (PCR)-restriction fragment length polymorphism method, using a standard method.
RESULTS: The polymorphic homozygote (T/T) genotype showed significantly an association with the incidence of gastric cancer compared with controls (P < 0.05).
CONCLUSIONS: This study suggests that C3435T polymorphism of the MDR1 gene may be associated with gastric cancer in an ethnic Iranian population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587910     DOI: 10.4103/0019-509X.64723

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  11 in total

1.  MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies.

Authors:  Xiaojing Sheng; Limei Zhang; Na Tong; Dewei Luo; Meilin Wang; Min Xu; Zhengdong Zhang
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

2.  MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case-control studies.

Authors:  Jun Wang; Baocheng Wang; Jingwang Bi; Kainan Li; Jianshi Di
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-23       Impact factor: 4.553

3.  Association of ABCB1 polymorphisms and ulcerative colitis susceptibility.

Authors:  Yanju Cao; Changmin Qu; Yan Chen; Lianyong Li; Xiaoying Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

4.  Can the prevalence of symptoms in patients with inflammatory bowel disease be predicted by the analysis of multidrug resistance gene 1 polymorphisms?

Authors:  Miguel Angel Chiurillo
Journal:  Saudi J Gastroenterol       Date:  2013 Jul-Aug       Impact factor: 2.485

5.  Simultaneous analysis of multidrug resistance 1(MDR1) C3435T, G2677T/A, and C1236T genotypes in Hamadan City population, West of Iran.

Authors:  Massoud Saidijam; Hossein Mahjub; Nooshin Shabab; Reza Yadegarazari
Journal:  Iran Biomed J       Date:  2015

6.  Association of ABCB1 (C3435T) and ABCC1 (G2012T) Polymorphisms with Clinical Response to Atorvastatin in Iranian Patients with Primary Hyperlipidemia.

Authors:  Niusha Behdad; Javad Kojuri; Negar Azarpira; Amir Masoomi; Soha Namazi
Journal:  Iran Biomed J       Date:  2016-05-30

Review 7.  HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.

Authors:  Atefeh Arab; Rezvan Yazdian-Robati; Javad Behravan
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2020-01-09       Impact factor: 4.291

8.  Association between single genetic polymorphisms of MDR1 gene and gastric cancer susceptibility in Chinese.

Authors:  Wen Qiao; Tao Wang; Li Zhang; Qing Tang; Dan Wang; Hongkun Sun
Journal:  Med Oncol       Date:  2013-06-26       Impact factor: 3.064

9.  The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case-control studies.

Authors:  Ling-Hui Wang; Yan-Bin Song; Wen-Ling Zheng; Ling Jiang; Wen-Li Ma
Journal:  Cancer Cell Int       Date:  2013-05-20       Impact factor: 5.722

10.  Impact of genetic variants of ABCB1, APOB, CAV1, and NAMPT on susceptibility to pancreatic ductal adenocarcinoma in Chinese patients.

Authors:  Baohuan Li; Chuanzhen Zhang; Jingjing Wang; Meijuan Zhang; Changhong Liu; Ziping Chen
Journal:  Mol Genet Genomic Med       Date:  2020-04-03       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.